Mirabegron + Placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Parkinsons Disease

Conditions

Parkinsons Disease

Trial Timeline

Mar 1, 2014 → Jul 1, 2018

NCT ID

NCT02092181

About Mirabegron + Placebo

Mirabegron + Placebo is a approved stage product being developed by Astellas Pharma for Parkinsons Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02092181. Target conditions include Parkinsons Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04641975	Phase 3	Terminated	Mar 15, 2021	Jul 24, 2023	Overactive Bladder (OAB)
NCT02787083	Phase 3	Terminated	Aug 1, 2016	Jul 5, 2019	Cystitis, Interstitial
NCT02216214	Approved	Completed	Oct 7, 2014	Jan 2, 2018	Overactive Bladder (OAB)
NCT02086188	Approved	Completed	May 1, 2014	Jun 1, 2019	Multiple Sclerosis
NCT02092181	Approved	Completed	Mar 1, 2014	Jul 1, 2018	Parkinsons Disease
NCT01284309	Phase 1	Completed	Nov 1, 2010	Feb 1, 2011	Intraocular Pressure
NCT00912964	Phase 3	Completed	Apr 28, 2009	Apr 27, 2010	Urinary Bladder, Overactive
NCT00662909	Phase 3	Completed	Mar 28, 2008	Apr 22, 2009	Urinary Bladder, Overactive
NCT00410514	Phase 2	Completed	Dec 1, 2006	Aug 1, 2008	Lower Urinary Tract Symptoms

Competing Products

5 competing products in Parkinsons Disease

See all competitors

Product	Company	Stage	Hype Score
Rivastigmine Patch 9.5 cm2	Novartis	Approved	85
Prasinezumab + Placebo	Roche	Phase 2	52
ALN-SNCA + Placebo	Regeneron Pharmaceuticals	Phase 1	32
bemdaneprocel	Bayer	Phase 3	74
High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule	Anavex Life Sciences	Phase 2	44

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved